Toxicities Rare After Two Weeks of CAR T-Cell Therapy Infusion
By Elana Gotkine HealthDay Reporter
TUESDAY, July 30, 2024 -- New-onset cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are rare beyond two weeks following infusion of CD19-directed chimeric antigen receptor T (CAR T)-cell therapies, according to a study published online July 23 in Blood Advances.
Noting that the U.S. Food and Drug Administration has mandated that patients should remain close to treatment centers for four weeks to monitor and manage toxicity risks associated with CD19-directed CAR T-cell therapies, including CRS and ICANS, Nausheen Ahmed, M.D., from the University of Kansas Medical Center in Westwood, and colleagues conducted a retrospective cohort study involving 475 patients infused with axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel from 2018 to 2023 to assess onset and duration of CRS and ICANS.
The researchers found that although there were differences in the incidence and duration of CRS and ICANS between CAR T-cell products, new-onset CRS and ICANS were extremely rare after two weeks following infusion, occurring in 0 and 0.7 percent, respectively. After two weeks, there were no new cases of CRS, while a single case of new-onset ICANS occurred in the third week following infusion. In the early follow-up period, nonrelapse mortality was driven by ICANS (1.1 percent until day 28), followed by infection through three months postinfusion (1.2 percent).
"These data support further investigation into individualized monitoring strategies for stable patients," the authors write. "A flexible monitoring period may help to decrease financial and geographic limitations for patients and make CAR T more accessible and feasible."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
Risk for Severe COVID-19 Elevated for Childhood Cancer Survivors
FRIDAY, July 11, 2025 -- Childhood cancer survivors have a lower risk for registered COVID-19 infection but a higher risk for severe COVID-19, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.